Topiramate augmentation in treatment-resistant obsessive–compulsive disorder: a retrospective, open-label case series

2006 ◽  
Vol 23 (1) ◽  
pp. 1-5 ◽  
Author(s):  
Michael Van Ameringen ◽  
Catherine Mancini ◽  
Beth Patterson ◽  
Mark Bennett
Keyword(s):  
Obsessive Compulsive Disorder ◽  
Case Series ◽  
Treatment Resistant ◽  
Obsessive Compulsive ◽  
Open Label ◽  
Compulsive Disorder

Quetiapine Augmentation of Selective Serotonin Reuptake Inhibitors in Treatment-Resistant Obsessive-Compulsive Disorder: A Six-Month Follow-Up Case Series

CNS Spectrums ◽  
2006 ◽  
Vol 11 (11) ◽  
pp. 879-883 ◽  
Author(s):  
Bernardo Dell'Osso ◽  
Emanuela Mundo ◽  
A. Carlo Altamura
Keyword(s):  
Obsessive Compulsive Disorder ◽  
Serotonin Reuptake ◽  
Selective Serotonin Reuptake Inhibitors ◽  
Case Series ◽  
Serotonin Reuptake Inhibitors ◽  
Selective Serotonin ◽  
Treatment Resistant ◽  
Obsessive Compulsive ◽  
Compulsive Disorder

ABSTRACTObsessive-compulsive disorder (OCD) is a relatively common, often chronic and disabling disorder with high rates of partial and/or absent response to standard, recommended treatments, such as selective serotonin reuptake inhibitors (SSRIs) and psychotherapy. This article presents the cases of four patients suffering from OCD and comorbid mood or anxiety disorders, who were treated with SSRIs at adequate doses for at least 12 weeks, showing a partial response. Quetiapine treatment was added to SSRIs at a dose of 25 mg/day and titrated up to 200 mg/day. Patients were followed up for 6 months. After 12 weeks, all the patients were classified as “much improved” on the Clinical Global Impression–Improvement scale and showed a Yale-Brown Obsessive-Compulsive Scale score reduction ≥35%. After 6 months of follow-up, all the patients maintained the same level of improvement. Although quetiapine augmentation to SSRIs has shown mixed results in published controlled trials in the acute treatment (12 weeks) of patients with treatment-resistant OCD, this case series indicates that patients who benefit from this pharmacologic regimen in the acute phase tend to maintain such an improvement. Larger follow-up studies are warranted to confirm our findings.

Riluzole Augmentation in Treatment-Resistant Obsessive–Compulsive Disorder: An Open-Label Trial

2005 ◽  
Vol 58 (5) ◽  
pp. 424-428 ◽  
Author(s):  
Vladimir Coric ◽  
Sarper Taskiran ◽  
Christopher Pittenger ◽  
Suzanne Wasylink ◽  
Daniel H. Mathalon ◽  
...  
Keyword(s):  
Obsessive Compulsive Disorder ◽  
Treatment Resistant ◽  
Obsessive Compulsive ◽  
Open Label ◽  
Compulsive Disorder ◽  
Open Label Trial

scholarly journals An open-label trial of memantine in treatment-resistant obsessive-compulsive disorder

2013 ◽  
Vol 22 (2) ◽  
pp. 149 ◽  
Author(s):  
Suprakash Chaudhury ◽  
AjayKumar Bakhla ◽  
Vijay Verma ◽  
Subhas Soren ◽  
Sujit Sarkhel
Keyword(s):  
Obsessive Compulsive Disorder ◽  
Treatment Resistant ◽  
Obsessive Compulsive ◽  
Open Label ◽  
Compulsive Disorder ◽  
Open Label Trial

Citalopram for treatment-resistant obsessive-compulsive disorder

1999 ◽  
Vol 14 (2) ◽  
pp. 101-106 ◽  
Author(s):  
S. Pallanti ◽  
L. Quercioli ◽  
R.S. Paiva ◽  
L.M. Koran
Keyword(s):  
Obsessive Compulsive Disorder ◽  
Treatment Resistant ◽  
Comparative Efficacy ◽  
Obsessive Compulsive ◽  
Open Label ◽  
Double Blind ◽  
Compulsive Disorder ◽  
Axis I ◽  
Open Label Trial ◽  
Percent Decrease

SummaryWe investigated the comparative efficacy of citalopram vs. citalopram administered with clomipramine, in treatment-resistant obsessive-compulsive disorder (OCD).Sixteen adult outpatients participated in a 90-day, randomized, open-label trial. Eligible patients were aged 18 to 45 years, had moderate to severe DSM-III-R OCD of ≥ one year's duration, a baseline Yale-Brown scale (Y-BOCS) score of ≥ 25 and no other active axis I diagnosis, and had failed adequate clomipramine and fluoxetine trials.The citalopram-plus-clomipramine group (n = 9) experienced a significantly larger percent decrease in mean Y-BOCS score by day 90 than the citalopram alone group (n = 7). Only one citalopram patient decreased her score by ≥ 35%, and two by ≥ 25%. All nine citalopram-plus-clomipramine patients experienced decreases of 35%. Side effects were mild to moderate in both groups. We also treated with citalopram six OCD patients who had not tolerated fluoxetine alone and clomipramine alone; three achieved Y-BOCS score decreases of ≥ 35% at 90 days.Since citalopram does not significantly affect clomipramine metabolism, the improvement in the combined drug group is unlikely to have resulted from increased plasma clomipramine levels. Double-blind controlled trials are needed of citalopram in OCD, and of combining citalopram with clomipramine in treatment-resistant OCD.

Sign in / Sign up

Export Citation Format

Share Document